Primary Prophylaxis against Invasive Fungal Infections (IFI) with Posaconazole (POS) or Voriconazole (VRC) Shows Better Efficacy Compared to No Systemic Prophylaxis during Induction and Consolidation Chemotherapy Cycles of Adult Acute Leukemia Patients

Mario E Ojeda Uribe, Catherine Berg, Alain Gravet, Eric Sauleau, Dominique Bourderont, and Celine Haby

Author address: 

Hematology, Hôpital E Muller, Mulhouse, France

Abstract: 

IFI are a well-known cause of severe morbidity and mortality in leukemic patients with chemotherapy induced neutropenia. From 2007 to date, during the induction and consolidation cycles of either de novo or relapsed adult leukemic patients we have administered a primary prophylaxis against IFI with the azole agents POS or VRC. This was compared to a two-year historical control without systemic primary prophylaxis. The whole population (mean age 51.3 yrs; n male =94; n female =43) included ALL patients (n cycles=33); AML (n cycles=88); transformed AREB-2 (n cycles=9); transformed CML (n cycles=7). Most of the chemotherapy regimens administered were those used by clinical trials of the GOELAMS and GRAALL French cooperative groups. Three periods were compared: 20052006 where no systemic primary prophylaxis was administered (n=63; mean age 47.2 yrs), the principal agent used was amphotericine B deoxycholate in oral suspension, 1000 mg (10 ml) thrice a day); January to September 2007 where VRC was administered either orally or intravenously 200 mg bid (n=23; mean age 51.1 yrs) and October 2007 to date where POS was administered orally at the standard dose of 200 mg (5ml) thrice a day (n=50; mean age 56 yrs). POS patients were significantly older (p
2008

abstract No: 

4834

Full conference title: 

50th American Society of Haematologists Annual Meeting
    • ASH 50th (2008)